Advertise on podcast: ASA Biopharm's Podcast

Jonathan Moscovici discusses BIOPs BRIDGE mentoring program.

Biopharmaceutical Section Chair Steven Novick discusses goals for the section.

Rebecca Wilson, Katie Brickey, John Kolassa, Jocelyn Sendecki, Paul Faya, and Mahan Dastgiri discuss the 2025 ASA Biopharmaceutical Section Nonclinical Biostatistics Conference.

Erik Bloomquist, Wanjie Sun, Yingwen Dong, and Jonathan Moscovici discuss what occurs behind the curtain at the Regulatory-Industry Statistics Workshop.

John McGready discusses how to prepare future statisticians to succeed in the era of AI.

A look at the life and accomplishments of Nan Laird.

Jürgen Hummel, Hiya Banerjee, Jingyi Liu, Jason Legg, and Henrik Ravn discuss the inaugural STATBOLIC Workshop.

Ian describes how to leverage ChatGPT to accelerate statistical programming in the medical product industry. Related paper available here: https://www.pharmasug.org/proceedings/2024/AP/PharmaSUG-2024-AP-256.pdf

Elaine Hoffman, Rebbecca Wilson, Christina Nurse, and Amy LaLonde discuss the balancing act between family and career.

Scott Clark,  Satrajit Roychoudhury, and Michelle Shardell discuss the Statistical Partnerships Among Academe, Industry & Government (SPAIG) Committee. https://community.amstat.org/spaig/home

Amy welcomes Rebbecca to the co-hosting chair while Christina enjoys some time off with her new baby (congrats)! The two discuss Rebbecca’s fascinating career thus far and how communication styles differ across male and female leaders. Reference: https://hbr.org/2022/12/research-men-speak-more-abstractly-than-women

Adrian and Wendy discuss imposter syndrome and being confident in your career.

In our first episode of the new year, we interview Steve Ruberg, an ASA fellow with over 35 years of experience in the biopharmaceutical industry and an active proponent of the Tripartite Estimand Approach.

Tian discusses her research in data integration methods and the bias arising from lack of representation.

LaShell discusses diversity, equity, and inclusion in clinical trials.